Combining patented technology in the areas of proteomics, genomics and bioinformatics and very active in the SBIR arena, AmberGen has developed technology platforms for the rapid analysis of DNA/RNA as well as of proteins. With the objective of making possible the identification of unique molecular fingerprints in tumors, blood and other biospecimens that are characteristic of specific diseases and their outcomes, for DNA/RNA analysis AmberGen has developed PhotoCleavable Mass Markers that enable high-throughput genetic analysis. Originally launched with the objective of commercializing certain proprietary cell-free protein expression and labeling technologies that had been developed at Boston University, AmberGen's proprietary molecular profiling technology enables physicians to more accurately make optimal therapeutic decisions tailored to individual patients.InAPril 2022, a substatntaul colboration was announced between Ambergen and Bruker orporation, one of the world's leading scientific instrumentation and life-science solutions companies
